Israel’s NeuroDerm raises $2.5M for patch-based Parkinson’s drug
Israel’s NeuroDerm (the page is currently a placeholder), a biotech developing drug patches for neurological disorders such as Parkinson’s disease, raised $2.5 million in a first round of funding. The investment was provided by private individuals, including Robert Taub, founder and CEO of Omrix Pharmaceuticals.
NeuroDerm, based in Ofakim, Israel, is at work on a skin patch that will allow continuous delivery of levadopa, a drug now used to treat Parkinson’s. Continuous delivery of the drug may help many patients avoid motor complications, the company says.
Next Story: AOL picks up Tacoda, behavior-based advertising network
Previous Story: KaloBios draws in $20M for antibody drugs
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.